[
  {
<<<<<<< HEAD
    "objectID": "index.html",
    "href": "index.html",
    "title": "Welcome to Jackie Ernest’s Website",
    "section": "",
    "text": "Explore research, applications, and more."
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "All publications can be found on Google Scholar page linked in upper right corner\n\n  \n    Sort by:\n    \n      Default\n      Year (Newest First)\n      Citations (Highest First)\n    \n  \n\n\n\n  \n    \n      \n        Optimizing hydroxychloroquine dosing for patients with COVID‐19: an integrative modeling approach for effective drug repurposing\n        Authors: Maria Garcia‐Cremades, Belen P Solans, Emma Hughes, Jacqueline P Ernest, Erika Wallender, Francesca Aweeka, Anne F Luetkemeyer, Radojka M Savic\n        Year: 2028Journal:Clinical Pharmacology & Therapeutics\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Development of new tuberculosis drugs: translation to regimen composition for drug-sensitive and multidrug-resistant tuberculosis\n        Authors: Jacqueline P Ernest, Natasha Strydom, Qianwen Wang, Nan Zhang, Eric Nuermberger, Véronique Dartois, Rada M Savic\n        Year: 2021Source: Annual review of pharmacology and toxicology\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis\n        Authors: Jacqueline P Ernest, Jansy Sarathy, Ning Wang, Firat Kaya, Matthew D Zimmerman, Natasha Strydom, Han Wang, Min Xie, Martin Gengenbacher, Laura E Via, Clifton E Barry III, Claire L Carter, Radojka M Savic, Véronique Dartois\n        Year: 2021Journal: Antimicrobial agents and chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders\n        Authors: Bitna Yi, Alam Jahangir, Andrew K Evans, Denise Briggs, Kristine Ravina, Jacqueline Ernest, Amir B Farimani, Wenchao Sun, Jayakumar Rajadas, Michael Green, Evan N Feinberg, Vijay S Pande, Mehrdad Shamloo\n        Year: 2017Journal: PLoS One\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        A rabbit model to study antibiotic penetration at the site of infection for nontuberculous mycobacterial lung disease: macrolide case study\n        Authors: Firat Kaya, Jacqueline P Ernest, Katherine LoMauro, Martin Gengenbacher, Abdeldjalil Madani, Wassihun Wedajo Aragaw, Matthew D Zimmerman, Jansy P Sarathy, Nadine Alvarez, Isaac Daudelin, Han Wang, Faye Lanni, Danielle M Weiner, Laura E Via, Clifton E Barry III, Kenneth N Olivier, Thomas Dick, Brendan K Podell, Radojka M Savic, Véronique Dartois\n        Year: 2022Journal: Antimicrobial agents and chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses\n        Authors: Nicholas D Walter, Jackie P Ernest, Christian Dide-Agossou, Allison A Bauman, Michelle E Ramey, Karen Rossmassler, Lisa M Massoudi, Samantha Pauly, Reem Al Mubarak, Martin I Voskuil, Firat Kaya, Jansy P Sarathy, Matthew D Zimmerman, Véronique Dartois, Brendan K Podell, Radojka M Savic, Gregory T Robertson\n        Year: 2023Journal: Antimicrobial agents and chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Pharmacometrics in tuberculosis: progress and opportunities\n        Authors: Author E, Author F\n        Year: 2022Source: \nInternational Journal of Antimicrobial Agents\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs\n        Authors: Jacqueline P Ernest, Janice Jia Ni Goh, Natasha Strydom, Qianwen Wang, Rob C van Wijk, Nan Zhang, Amelia Deitchman, Eric Nuermberger, Rada M Savic\n        Year: 2023Journal: European Respiratory Journal\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modeling study\n        Authors: Kendra K Radtke, Jacqueline P Ernest, Nan Zhang, Nicole C Ammerman, Eric Nuermberger, Robert Belknap, Rosanna Boyd, Timothy R Sterling, Rada M Savic\n        Year: 2021Journal: Antimicrobial agents and chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen\n        Authors: Natasha Strydom, Jacqueline P Ernest, Marjorie Imperial, Belén P Solans, Qianwen Wang, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Andrew Garcia, Kristina Bigelow, Martin Gengenbacher, Matthew Zimmerman, Min Xie, Jansy P Sarathy, Tian J Yang, Véronique Dartois, Eric L Nuermberger, Radojka M Savic\n        Year: 2024Journal: Nature communications\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing\n        Authors: Garcia‐Cremades Maria, P Solans Belen, Hughes Emma, P Ernest Jacqueline, Wallender Erika, Aweeka Francesca, Luetkemeyer Annie, M Savic Radojka\n        Year: 2020Journal: Clin Pharmacol Ther\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        PREDICTING THE EARLY BACTERICIDAL ACTIVITY (EBA) OF TUBERCULOSIS (TB) DRUGS FOR THE PHASE IIA FIRST-IN-PATIENTS STUDIES.\n        Authors: N Zhang, N Strydom, Q Wang, J Ernest, E Nuermberger, R Savic\n        Year: 2020Conference: CLINICAL PHARMACOLOGY & THERAPEUTICS\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        LIMITED PENETRATION AND EFFICACY OF AMINOGLYCOSIDES IN LESIONS OF TUBERCULOSIS: A TRANSLATIONAL SITE-OF-ACTION PKPD MODELING STUDY.\n        Authors: J Ernest, N Strydom, J Sarathy, M Zimmerman, V Dartois, R Savic\n        Year: 2021Journal: Journal Twelve\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy-or hard-to-treat tuberculosis disease\n        Authors: Nathan Peroutka-Bigus, Elizabeth J Brooks, Michelle E Ramey, Hope D'Erasmo, Jackie P Ernest, Allison A Bauman, Lisa K Woolhiser, Radojka M Savic, Anne J Lenaerts, Bree B Aldridge, Jansy P Sarathy, Gregory T Robertson\n        Year: 2025Journal: Antimicrobial Agents and Chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models\n        Authors: Bernard Ngara, Lorenzo Flori, Rob Christiaan van Wijk, Jacqueline P Ernest, Sandeep Tyagi, Heena Soni, Christoph Hölscher, Kerstin Walter, Julia Dreisbach, Michael Hoelscher, Eric L Nuermberger, Radojka M Savic\n        Year: 2025Journal: The Journal of Infectious Diseases\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Selection and prioritization of candidate combination regimens for the treatment of tuberculosis\n        Authors: Natasha Strydom, Rob C van Wijk, Qianwen Wang, Jacqueline P Ernest, Linda Chaba, Ziran Li, Eric L Nuermberger, Radojka M Savic\n        Year: 2025Journal: Science Translational Medicine\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        The kinetics of bedaquiline diffusion in tuberculous cavities opens a window for emergence of resistance\n        Authors: Annamarie E Bustion, Jacqueline P Ernest, Firat Kaya, Connie Silva, Jansy Sarathy, Landry Blanc, Marjorie Imperial, Martin Gengenbacher, Min Xie, Matthew Zimmerman, Gregory T Robertson, Danielle Weiner, Laura E Via, Clifton E Barry, Radojka M Savic, Véronique Dartois\n        Year: 2024Journal: bioRxiv\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        It's That Time of Year-Give Yourself the Gift of SCIENCE!\n        Authors: Jacqueline Ernest\n        Year: 2023Source: CLINICAL PHARMACOLOGY & THERAPEUTICS\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        GATIFLOXACIN EXPOSURE IN THE LESION AS TARGET SITE OF GATIFLOXACIN IN A RABBIT MODEL OF TUBERCULOSIS: COMPARISON WITH THE OUTCOMES FROM THE PHASE III OFLOTUB TRIAL.\n        Authors: L Flori, J Ernest, M Zimmerman, V Dartois, R Savic\n        Year: 2023Source: CLINICAL PHARMACOLOGY & THERAPEUTICS\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        A LESION-CENTRIC AND TARGET-SPECIFIC PKPD MODEL OF PYRAZINOIC ACID IN PATIENTS WITH TUBERCULOSIS\n        Authors: A Fochesato, J Ernest, V Dartois, R Savic\n        Year: 2023Conference: CLINICAL PHARMACOLOGY & THERAPEUTICS\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Translating Nonclinical Findings to Prioritize Sterilizing Multi-Drug Regimens for the Treatment of Tuberculosis\n        Authors: Jacqueline Ernest\n        Year: 2022Institution: University of California, San Francisco\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data”\n        Authors: Maria Garcia‐Cremades, Belen P Solans, Emma Hughes, Jacqueline P Ernest, Erika Wallender, Radojka M Savic\n        Year: 2020Journal: Clinical Pharmacology and Therapeutics\n      \n      \n        View Publication"
  },
  {
=======
>>>>>>> 63a5c8c ("revert back to fixed hero-image and layout")
    "objectID": "documents.html",
    "href": "documents.html",
    "title": "Installing NONMEM",
    "section": "",
    "text": "This instruction works with macOS13 (Ventura) and later versions. Not all steps are necessary depending on your Mac’s existing configuration. All commands can be executed in terminal, such as Terminal.app, Mac’s built-in terminal, and VSCode.\n\n\nxcode-select --install\n\n\n\nGCC is a collections of tools required to install NONMEM. NONMEM is only compatible with GCC version 11 or earlier.\nTo install GCC Ver.11, we need to install Homebrew first, which is a package management tool for MacOS and Linux. Run the command in the terminal:\n/bin/bash -c \"$(curl -fsSL https://raw.githubusercontent.com/Homebrew/install/HEAD/install.sh)\"\nOnce Homebrew is installed. Run this command to install GCC Ver.11:\nbrew install gcc@11\nGCC@11 installs gcc-11 and gfortran-11 commands, which are necessary to compile NONMEM source files. However, NONMEM only recognize gcc and gfortran commands. You can use either methods below to resolve this issue:\n\n\nWe can create symbolic links to make gcc and gfortran point to gcc-11 and gcc-fortran using the following commands:\nsudo ln -s $(which gcc-11) /usr/local/bin/gcc\nsudo ln -s $(which gfortran-11) /usr/local/bin/gfortran\nRun this command to verify the symbolic links:\nwhich gcc\nwhich gfortran\nThe following messages should return:\n/usr/local/bin/gcc\n/usr/local/bin/gfortran\n\n\n\nWe can set gcc and gfortran as aliases for gcc-11 and gfortran-11 using the following commands:\necho 'alias gcc=\"gcc-11\"' &gt;&gt; ~/.zprofile\necho 'alias gfortran=\"gfortran-11\"' &gt;&gt; ~/.zprofile\nReload shell configuration for alias to take effect:\nsource ~/.zprofile\nVerify the configuration:\nwhich gcc\nwhich gfortran\nThese messages should show up:\ngcc: aliased to gcc-11\ngfortran: aliased to gfortran-11\n\n\n\n\nIf MacOS flagged NONMEM as an application from an unverified developer and triggered Gatekeeper security preventing installation. We can temporarily disable Gatekeeper:\nsudo spctl --global-disable\n\n\n\nAssuming the NONMEM source file folder is located at ~/Downloads/NM751CD, and the target installation location is /opt/nm751.\nWe first navigate to the NONMEM source directory:\ncd ~/Downloads/NM751CD \nRun the command below to initiate the NONMEM installation:\nsudo /bin/bash ./SETUP75 ~/Downloads/NM751CD /opt/nm751 gfortran\nYou will be prompted to enter your password, after which you can follow the installation wizard to complete the process.\nFinally, after the installation is complete, remember to re-enable Gatekeeper:\nsudo spctl --global-enable\n*As of Dec 2024, the following configurations have been successfully tested.\n\n\n\nDevice\nmacOS\nGCC\nNONMEM\n\n\n\n\nMacbook Pro (M1, 2020)\nBig Sur\n10.2 x86\n7.5.1\n\n\nMacbook Pro (M1, 2020)\nMonterey\n11.3 ARM\n7.5.1\n\n\nMacbook Pro (M1, 2020)\nVentura\n11.5 ARM\n7.5.1\n\n\nMacbook Pro (M3 Pro, 2023)\nSonoma\n11.3 x86\n7.5.1\n\n\nMacbook Pro (M3 Pro, 2023)\nSequoia\n11.5 ARM\n7.5.1\n\n\nMacbook Pro (M4 Pro, 2024)\nSequoia\n11.5 ARM\n7.6.0"
  },
  {
    "objectID": "documents.html#macos",
    "href": "documents.html#macos",
    "title": "Installing NONMEM",
    "section": "",
    "text": "This instruction works with macOS13 (Ventura) and later versions. Not all steps are necessary depending on your Mac’s existing configuration. All commands can be executed in terminal, such as Terminal.app, Mac’s built-in terminal, and VSCode.\n\n\nxcode-select --install\n\n\n\nGCC is a collections of tools required to install NONMEM. NONMEM is only compatible with GCC version 11 or earlier.\nTo install GCC Ver.11, we need to install Homebrew first, which is a package management tool for MacOS and Linux. Run the command in the terminal:\n/bin/bash -c \"$(curl -fsSL https://raw.githubusercontent.com/Homebrew/install/HEAD/install.sh)\"\nOnce Homebrew is installed. Run this command to install GCC Ver.11:\nbrew install gcc@11\nGCC@11 installs gcc-11 and gfortran-11 commands, which are necessary to compile NONMEM source files. However, NONMEM only recognize gcc and gfortran commands. You can use either methods below to resolve this issue:\n\n\nWe can create symbolic links to make gcc and gfortran point to gcc-11 and gcc-fortran using the following commands:\nsudo ln -s $(which gcc-11) /usr/local/bin/gcc\nsudo ln -s $(which gfortran-11) /usr/local/bin/gfortran\nRun this command to verify the symbolic links:\nwhich gcc\nwhich gfortran\nThe following messages should return:\n/usr/local/bin/gcc\n/usr/local/bin/gfortran\n\n\n\nWe can set gcc and gfortran as aliases for gcc-11 and gfortran-11 using the following commands:\necho 'alias gcc=\"gcc-11\"' &gt;&gt; ~/.zprofile\necho 'alias gfortran=\"gfortran-11\"' &gt;&gt; ~/.zprofile\nReload shell configuration for alias to take effect:\nsource ~/.zprofile\nVerify the configuration:\nwhich gcc\nwhich gfortran\nThese messages should show up:\ngcc: aliased to gcc-11\ngfortran: aliased to gfortran-11\n\n\n\n\nIf MacOS flagged NONMEM as an application from an unverified developer and triggered Gatekeeper security preventing installation. We can temporarily disable Gatekeeper:\nsudo spctl --global-disable\n\n\n\nAssuming the NONMEM source file folder is located at ~/Downloads/NM751CD, and the target installation location is /opt/nm751.\nWe first navigate to the NONMEM source directory:\ncd ~/Downloads/NM751CD \nRun the command below to initiate the NONMEM installation:\nsudo /bin/bash ./SETUP75 ~/Downloads/NM751CD /opt/nm751 gfortran\nYou will be prompted to enter your password, after which you can follow the installation wizard to complete the process.\nFinally, after the installation is complete, remember to re-enable Gatekeeper:\nsudo spctl --global-enable\n*As of Dec 2024, the following configurations have been successfully tested.\n\n\n\nDevice\nmacOS\nGCC\nNONMEM\n\n\n\n\nMacbook Pro (M1, 2020)\nBig Sur\n10.2 x86\n7.5.1\n\n\nMacbook Pro (M1, 2020)\nMonterey\n11.3 ARM\n7.5.1\n\n\nMacbook Pro (M1, 2020)\nVentura\n11.5 ARM\n7.5.1\n\n\nMacbook Pro (M3 Pro, 2023)\nSonoma\n11.3 x86\n7.5.1\n\n\nMacbook Pro (M3 Pro, 2023)\nSequoia\n11.5 ARM\n7.5.1\n\n\nMacbook Pro (M4 Pro, 2024)\nSequoia\n11.5 ARM\n7.6.0"
  },
  {
    "objectID": "documents.html#windows",
    "href": "documents.html#windows",
    "title": "Installing NONMEM",
    "section": "Windows",
    "text": "Windows\nNONMEM allows one-click installations for Windows environment. You can find the file on NONMEM’s official page https://nonmem.iconplc.com/#/nonmem751 by copying and pasting the link to your browser. The file name should be similar in format to NONMEM751_64gfortran463.exe.\nAdditional documents can be found in “Additional Documents” in dropdown menu"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Welcome to Jackie Ernest’s Website",
    "section": "",
    "text": "Welcome to Jackie Ernest’s Website\n    Explore research, applications, and more."
  },
  {
    "objectID": "projects.html#project-2",
    "href": "projects.html#project-2",
    "title": "Projects",
    "section": "Project 2",
    "text": "Project 2"
  },
  {
    "objectID": "projects.html#project-3",
    "href": "projects.html#project-3",
    "title": "Projects",
    "section": "Project 3",
    "text": "Project 3"
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "All publications can be found on Google Scholar page linked in upper right corner\n\n  \n    Sort by:\n    \n      Default\n      Year (Newest First)\n      Citations (Highest First)\n    \n  \n\n\n\n  \n    \n      \n        Optimizing hydroxychloroquine dosing for patients with COVID‐19: an integrative modeling approach for effective drug repurposing\n        Authors: Maria Garcia‐Cremades, Belen P Solans, Emma Hughes, Jacqueline P Ernest, Erika Wallender, Francesca Aweeka, Anne F Luetkemeyer, Radojka M Savic\n        Year: 2028Journal:Clinical Pharmacology & Therapeutics\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Development of new tuberculosis drugs: translation to regimen composition for drug-sensitive and multidrug-resistant tuberculosis\n        Authors: Jacqueline P Ernest, Natasha Strydom, Qianwen Wang, Nan Zhang, Eric Nuermberger, Véronique Dartois, Rada M Savic\n        Year: 2021Source: Annual review of pharmacology and toxicology\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis\n        Authors: Jacqueline P Ernest, Jansy Sarathy, Ning Wang, Firat Kaya, Matthew D Zimmerman, Natasha Strydom, Han Wang, Min Xie, Martin Gengenbacher, Laura E Via, Clifton E Barry III, Claire L Carter, Radojka M Savic, Véronique Dartois\n        Year: 2021Journal: Antimicrobial agents and chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders\n        Authors: Bitna Yi, Alam Jahangir, Andrew K Evans, Denise Briggs, Kristine Ravina, Jacqueline Ernest, Amir B Farimani, Wenchao Sun, Jayakumar Rajadas, Michael Green, Evan N Feinberg, Vijay S Pande, Mehrdad Shamloo\n        Year: 2017Journal: PLoS One\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        A rabbit model to study antibiotic penetration at the site of infection for nontuberculous mycobacterial lung disease: macrolide case study\n        Authors: Firat Kaya, Jacqueline P Ernest, Katherine LoMauro, Martin Gengenbacher, Abdeldjalil Madani, Wassihun Wedajo Aragaw, Matthew D Zimmerman, Jansy P Sarathy, Nadine Alvarez, Isaac Daudelin, Han Wang, Faye Lanni, Danielle M Weiner, Laura E Via, Clifton E Barry III, Kenneth N Olivier, Thomas Dick, Brendan K Podell, Radojka M Savic, Véronique Dartois\n        Year: 2022Journal: Antimicrobial agents and chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses\n        Authors: Nicholas D Walter, Jackie P Ernest, Christian Dide-Agossou, Allison A Bauman, Michelle E Ramey, Karen Rossmassler, Lisa M Massoudi, Samantha Pauly, Reem Al Mubarak, Martin I Voskuil, Firat Kaya, Jansy P Sarathy, Matthew D Zimmerman, Véronique Dartois, Brendan K Podell, Radojka M Savic, Gregory T Robertson\n        Year: 2023Journal: Antimicrobial agents and chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Pharmacometrics in tuberculosis: progress and opportunities\n        Authors: Author E, Author F\n        Year: 2022Source: \nInternational Journal of Antimicrobial Agents\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs\n        Authors: Jacqueline P Ernest, Janice Jia Ni Goh, Natasha Strydom, Qianwen Wang, Rob C van Wijk, Nan Zhang, Amelia Deitchman, Eric Nuermberger, Rada M Savic\n        Year: 2023Journal: European Respiratory Journal\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modeling study\n        Authors: Kendra K Radtke, Jacqueline P Ernest, Nan Zhang, Nicole C Ammerman, Eric Nuermberger, Robert Belknap, Rosanna Boyd, Timothy R Sterling, Rada M Savic\n        Year: 2021Journal: Antimicrobial agents and chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n\n  \n    \n      \n        Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen\n        Authors: Natasha Strydom, Jacqueline P Ernest, Marjorie Imperial, Belén P Solans, Qianwen Wang, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Andrew Garcia, Kristina Bigelow, Martin Gengenbacher, Matthew Zimmerman, Min Xie, Jansy P Sarathy, Tian J Yang, Véronique Dartois, Eric L Nuermberger, Radojka M Savic\n        Year: 2024Journal: Nature communications\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing\n        Authors: Garcia‐Cremades Maria, P Solans Belen, Hughes Emma, P Ernest Jacqueline, Wallender Erika, Aweeka Francesca, Luetkemeyer Annie, M Savic Radojka\n        Year: 2020Journal: Clin Pharmacol Ther\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        PREDICTING THE EARLY BACTERICIDAL ACTIVITY (EBA) OF TUBERCULOSIS (TB) DRUGS FOR THE PHASE IIA FIRST-IN-PATIENTS STUDIES.\n        Authors: N Zhang, N Strydom, Q Wang, J Ernest, E Nuermberger, R Savic\n        Year: 2020Conference: CLINICAL PHARMACOLOGY & THERAPEUTICS\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        LIMITED PENETRATION AND EFFICACY OF AMINOGLYCOSIDES IN LESIONS OF TUBERCULOSIS: A TRANSLATIONAL SITE-OF-ACTION PKPD MODELING STUDY.\n        Authors: J Ernest, N Strydom, J Sarathy, M Zimmerman, V Dartois, R Savic\n        Year: 2021Journal: Journal Twelve\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy-or hard-to-treat tuberculosis disease\n        Authors: Nathan Peroutka-Bigus, Elizabeth J Brooks, Michelle E Ramey, Hope D'Erasmo, Jackie P Ernest, Allison A Bauman, Lisa K Woolhiser, Radojka M Savic, Anne J Lenaerts, Bree B Aldridge, Jansy P Sarathy, Gregory T Robertson\n        Year: 2025Journal: Antimicrobial Agents and Chemotherapy\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models\n        Authors: Bernard Ngara, Lorenzo Flori, Rob Christiaan van Wijk, Jacqueline P Ernest, Sandeep Tyagi, Heena Soni, Christoph Hölscher, Kerstin Walter, Julia Dreisbach, Michael Hoelscher, Eric L Nuermberger, Radojka M Savic\n        Year: 2025Journal: The Journal of Infectious Diseases\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Selection and prioritization of candidate combination regimens for the treatment of tuberculosis\n        Authors: Natasha Strydom, Rob C van Wijk, Qianwen Wang, Jacqueline P Ernest, Linda Chaba, Ziran Li, Eric L Nuermberger, Radojka M Savic\n        Year: 2025Journal: Science Translational Medicine\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        The kinetics of bedaquiline diffusion in tuberculous cavities opens a window for emergence of resistance\n        Authors: Annamarie E Bustion, Jacqueline P Ernest, Firat Kaya, Connie Silva, Jansy Sarathy, Landry Blanc, Marjorie Imperial, Martin Gengenbacher, Min Xie, Matthew Zimmerman, Gregory T Robertson, Danielle Weiner, Laura E Via, Clifton E Barry, Radojka M Savic, Véronique Dartois\n        Year: 2024Journal: bioRxiv\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        It's That Time of Year-Give Yourself the Gift of SCIENCE!\n        Authors: Jacqueline Ernest\n        Year: 2023Source: CLINICAL PHARMACOLOGY & THERAPEUTICS\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        GATIFLOXACIN EXPOSURE IN THE LESION AS TARGET SITE OF GATIFLOXACIN IN A RABBIT MODEL OF TUBERCULOSIS: COMPARISON WITH THE OUTCOMES FROM THE PHASE III OFLOTUB TRIAL.\n        Authors: L Flori, J Ernest, M Zimmerman, V Dartois, R Savic\n        Year: 2023Source: CLINICAL PHARMACOLOGY & THERAPEUTICS\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        A LESION-CENTRIC AND TARGET-SPECIFIC PKPD MODEL OF PYRAZINOIC ACID IN PATIENTS WITH TUBERCULOSIS\n        Authors: A Fochesato, J Ernest, V Dartois, R Savic\n        Year: 2023Conference: CLINICAL PHARMACOLOGY & THERAPEUTICS\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Translating Nonclinical Findings to Prioritize Sterilizing Multi-Drug Regimens for the Treatment of Tuberculosis\n        Authors: Jacqueline Ernest\n        Year: 2022Institution: University of California, San Francisco\n      \n      \n        View Publication\n      \n    \n  \n  \n  \n    \n      \n        Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data”\n        Authors: Maria Garcia‐Cremades, Belen P Solans, Emma Hughes, Jacqueline P Ernest, Erika Wallender, Radojka M Savic\n        Year: 2020Journal: Clinical Pharmacology and Therapeutics\n      \n      \n        View Publication"
  },
  {
    "objectID": "applications.html",
    "href": "applications.html",
    "title": "Applications",
    "section": "",
    "text": "All code and data can be found on Github linked in upper right corner.\nIf you have any questions regarding the applications, please reach out through email linked in the upper right corner. Thank you!"
  },
  {
    "objectID": "applications.html#cr-simulator",
    "href": "applications.html#cr-simulator",
    "title": "Applications",
    "section": "CR Simulator",
    "text": "CR Simulator\nResponses over Concentration profile"
  },
  {
    "objectID": "applications.html#pk-simulator",
    "href": "applications.html#pk-simulator",
    "title": "Applications",
    "section": "PK Simulator",
    "text": "PK Simulator\nPK profile over time(h)"
  },
  {
    "objectID": "applications.html#bootcamp-pk-simulator",
    "href": "applications.html#bootcamp-pk-simulator",
    "title": "Applications",
    "section": "Bootcamp PK Simulator",
    "text": "Bootcamp PK Simulator\nThis contains changes to PK simulator R shiny app specific to bootcamp 2020\nPK profile over time with new features\n\n\n\n\n\nDataset here (.csv)"
  }
]